BioWorld Asia

Sep. 17, 2008

View Archived Issues

Blocking Heat Shock Proteins Points to More Selective Drugs

Unibioscreen Gets Up to $31M in Cancer Drug Deal with Drais

NicOx Shows Positive Data From 2nd Naproxcinod Trial

Polyplus-transfection Develops New Class of Oligonucleotides

Biomarker Data Point to Target Patients for Transgene's Vaccine

CV Therapeutics Gets $70M Up Front in Ex-U.S. Ranexa Deal

Other News To Note

Cell Medica Begins Study of CMV Transplant Therapy

LONDON - Cell Medica Ltd. has treated the first patient in a Phase III trial of a cell therapy treatment for the prevention of cytomegalovirus (CMV) infection in immunocompromised bone marrow transplant patients. (BioWorld International) Read More

HemoCORM, Alfama Align in Carbon Monoxide Deal

Today's news in brief

BioWorld

BioWorld briefs for July 28, 2026.

News in brief

BioWorld Asia

BioWorld Asia briefs for July 28, 2026

Brain-penetrant NLRP3 inhibitor shows promise in Parkinson’s

BioWorld Science

Researchers from Changchun Genescience Pharmaceuticals Co. Ltd. described the discovery and preclinical profile of an NLRP3 inhibitor with favorable brain...

Daybu readthrough in EU? Zevra’s NPC bid flounders

BioWorld

Zevra Therapeutics Inc. will try to follow in the footsteps of Acadia Pharmaceuticals Inc. with Rett syndrome drug Daybu (trofinetide) by asking the EMA’s...

Transcripta Bio raises funding to advance neuro pipeline

BioWorld Science

Transcripta Bio Inc. has raised $24 million since its series A to fund IND-enabling studies across its portfolio and support clinical preparation in its autism...